PONTE
VEDRA, Fla., Nov. 30,
2023 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a late-stage novel oral and reversible anticoagulant
(blood thinner) designed to prevent heart attacks, strokes and
deaths due to blood clots in patients with certain rare medical
conditions, announced today that Quang
Pham, CEO, will present at NobleCon19 - Noble Capital
Markets' Nineteenth (19) Annual Emerging Growth Equity Conference
at Florida Atlantic University,
Executive Education Complex, in Boca
Raton, FL on Monday, December
4 at 4:00 p.m. Eastern time.
There is also the opportunity to meet the management at a breakout
session scheduled immediately following the presentation.
A high-definition video webcast of the presentation will be
available the following day on the Company's website at
www.cadrenal.com/investors, and as part of a complete catalog of
presentations available at Noble Capital Markets' Conference
website: www.nobleconference.com and on Channelchek
www.channelchek.com the investor portal created by Noble. The
webcast will be archived on the company's website, the NobleCon
website, and on Channelchek.com for 90 days following the
event.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a
late-stage novel oral and reversible anticoagulant (blood thinner),
to prevent heart attacks, strokes, and deaths due to blood clots in
patients with certain rare medical conditions who require chronic
anticoagulation. Tecarfarin has orphan drug and Fast
Track designations for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients
with end-stage kidney disease (ESKD) with atrial
fibrillation (AFib), and also is being evaluated for
the treatment of heart disease in patients with implanted medical
devices such as left ventricular assist devices
(LVADs), as well as in patients with
antiphospholipid syndrome (APS).
Tecarfarin is specifically designed to leverage a different
metabolic pathway than the oldest and most commonly prescribed
Vitamin K Antagonist (warfarin) used in
the prevention of thrombosis. Tecarfarin has been
evaluated in eleven (11) human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated
in both healthy adult subjects and patients with chronic kidney
disease. For more information, please visit:
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing
Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-present-at-the-noblecon-19-conference-on-december-4-2023-302002437.html
SOURCE Cadrenal Therapeutics, Inc.